Scopus BioPharma (NASDAQ:SCPS – Get Free Report) will likely be issuing its resultson Wednesday, September 2nd. Analysts expect Scopus BioPharma to post earnings of ($0.22) per share for the quarter.
Scopus BioPharma Stock Performance
SCPS stock opened at $0.00 on Monday. Scopus BioPharma has a 52-week low of $0.00 and a 52-week high of $0.01.
Scopus BioPharma Company Profile
Scopus BioPharma, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for central nervous system disorders. The company’s research efforts are aimed at addressing unmet medical needs in neuropathic pain, migraine and mood disorders by leveraging proprietary small-molecule platforms designed to modulate key neural pathways.
The company’s product pipeline comprises both clinical- and preclinical-stage candidates. Its lead programs include small-molecule compounds intended to provide relief in patients suffering from chronic neuropathic pain and episodic migraine.
Further Reading
- Five stocks we like better than Scopus BioPharma
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
